Jeffrey A Meckler Indaptus Therapeutics, Inc. (INDP) insider trading activity

Jeffrey A Meckler is Co-Chief Executive Officer of Indaptus Therapeutics, Inc.. Currently has a direct ownership of 229,929 shares of INDP, which is worth approximately $577,121. The most recent transaction as insider was on Dec 22, 2025, when has been sold 216,617 shares (Common Stock) at a price of $2.03 per share, resulting in proceeds of $439,732. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 230K

1627.23% 3M change

13.34% 12M change

Total Value Held $577,121

Jeffrey A Meckler Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 22 2025	BUY Grant, award, or other acquisition	$439,732 $2.03 p/Share	216,617 Added 48.51%	229,929 Common Stock
Jul 27 2025	BUY Grant, award, or other acquisition	$50,364 $8.3 p/Share	6,068 Added 31.31%	13,312 Common Stock
Nov 25 2024	BUY Grant, award, or other acquisition	$50,212 $1.18 p/Share	42,553 Added 17.34%	202,859 Common Stock
Aug 08 2024	BUY Grant, award, or other acquisition	$154,576 $1.82 p/Share	84,932 Added 34.63%	160,306 Common Stock
Nov 21 2022	BUY Open market or private purchase	$18,240 $1.9 p/Share	9,600 Added 11.3%	75,374 Common Stock
Nov 18 2022	BUY Open market or private purchase	$704 $1.76 p/Share	400 Added 0.6%	65,774 Common Stock
Sep 08 2022	BUY Open market or private purchase	$28,862 $2.8 p/Share	10,308 Added 13.62%	65,374 Common Stock

Sep 07 2022	BUY Open market or private purchase	$22,184 $2.57 p/Share	8,632 Added 13.55%	55,066 Common Stock
Sep 06 2022	BUY Open market or private purchase	$2,586 $2.44 p/Share	1,060 Added 2.23%	46,434 Common Stock
Jun 06 2022	BUY Open market or private purchase	$51,882 $2.63 p/Share	19,727 Added 30.3%	45,374 Common Stock
Nov 18 2021	BUY Open market or private purchase	$65,108 $5.82 p/Share	11,187 Added 30.37%	25,647 Common Stock
Sep 14 2021	BUY Open market or private purchase	$84,000 $7.0 p/Share	12,000 Added 45.35%	14,460 Common Stock

Also insider at

TVTX

Travere Therapeutics, Inc. Healthcare

JAM